﻿ All about micro-immunotherapy - PAPILLOMA ®

All about Micro-immunotherapy

Élément au microscope

What Is Micro-Immunotherapy?

Main avec molécule


Micro-immunotherapy is a modern therapy that aims of restoring or optimizing communication between immune system cells, impaired in most diseases. Micro-immunotherapy uses the same mediators in a specific order and by respecting the natural mechanisms of the body to transmit information to the body and “readjust” the immune response.

Thus, micro-immunotherapy provides the immune system with the tools it needs to effectively fight what can affect our health.


History of the discipline

The history of micro-immunotherapy begins with Dr. Maurice Jenaer, a Belgian doctor and researcher who aimed at achieving satisfactory clinical results in harmony with physiology, that is, through the application of a mild immunotherapy without side effects.

The concept of micro-immunotherapy developed by Dr. Jenaer was born in the years 1967 and 1968 when he understood by accident that DNA and RNA could be absorbed sublingually after dilution and dynamisation.

Later, in the 1970s, he was able to verify that this same property also applied to cytokines, the messengers of dialogue between the defense units of our immune system. It was on these two bases that Dr. Jenaer began to develop micro-immunotherapy.

Portrait du docteur Maurice Jenaer

What are the benefits of micro-immunotherapy?

Micro-immunotherapy medicines use immune substances prepared in low concentrations via a dilution- dynamisation process that ensures good tolerance. These substances are administered in a specific order with different levels of dilution within the same formula, depending on whether we try to stimulate, modulate or slow down their effects on the body.

Micro-immunotherapy is an ally in the treatment of acute or chronic diseases related to a disbalance of the immune system, such as infectious diseases, oncology or autoimmune diseases.

However, micro-immunotherapy never replaces the immune system, it does not force or block it but subtly informs it, which makes it compatible with other treatments.

Labo'Life, pioneer of micro-immunotherapy

Our vision of micro-immunotherapy

Labo’Life medicines are designed to support and restore the effectiveness of the immune system in a global therapeutic strategy which takes into account the specific circumstances and needs of the patient. At Labo’Life, good health is the result of a balance influenced by several factors, such as genetic heritage and the environment. However, this self-regulating ability of the immune system to manage internal and external influences is sometimes impaired, leading to the onset of disease.

Therefore Labo’Life helps the patient to establish a therapeutic strategy that takes into account the immune system, the central pillar of our health.

History of the Labo’Life Group

Labo’Life France was founded in 1992 by Mr. Christian Foissey with the help of a French private shareholding and, in December, the first production unit of the Labo’Life group was set up in Consell (Mallorca). The production was launched in August 1993 when Labo’Life España received the authorization for the manufacture of medicines for human use from the Spanish Agency for Medicines and Sanitary Products (AEMPS). Between June and July 2000 Labo’Life Belgium and Labo’Life Italia (Milan) were created, with a new pharmaceutical distribution unit in Belgium. In 2004, Labo’Life Belgium, located at the Crealys Science Park in Gembloux, became a production laboratory.



Medicine Production Department
Micro-immunotherapy medicines are manufactured by Labo’Life’s Medicine Production Department. Once analyzed by the quality control laboratory and released (verification of their compliance) by the responsible pharmacist, the active substances of the medicine (cytokines, nucleic acids, etc.) and the packaging materials can integrate the GMP production process

R+D and Active Ingredients Production Department (AIP)
R+D and Active Ingredients Production Department (AIP) is responsible for the development and optimization of biotechnology processes for the extraction and purification of cytokines used in Labo’Life medicines.

Clinical Evaluations Department
The Clinical Evaluation Department has a dual mission:

  1. Collect and analyze clinical data from prescribing physicians in retrospective studies, especially for the scientific recognition of micro-immunotherapy.
  2. Set up prospective studies versus placebo or control group, meeting the Standards of Good Clinical Practice and validated by health authorities and ethics committees, to confirm the effectiveness of Labo’Life medicines.